Company & Team

Neusignal Therapeutics is dedicated to improving Quality of Life for patients and all those affected by Central Nervous System (CNS) diseases, including dementia, which are rapidly increasing due to global population aging. We aim to achieve this through the development of groundbreaking therapeutic drugs.

MEMBER

Itaru Arimoto
Ph.D.
Chief Executive Officer

Dr. Arimoto began his career in research at Eisai Co., Ltd., where he was responsible for the development and regulatory approval of donepezil, leading the team for nine years. He then joined Asahi Kasei Pharma Corporation, serving as Head of Development and Regulatory Affairs, Head of Overseas Clinical Development, and later as Head of Clinical Planning, overseeing and coordinating all development pipelines. He subsequently served as President of Asahi Kasei Group’s overseas subsidiaries for three and a half years. He holds a B.A. from Kyoto University and a Ph.D. in Pharmaceutical Sciences from the Graduate School of Pharmaceutical Sciences, Kyoto University.

Shigeki Moriguchi
Ph.D.

(Associate Professor, Graduate School of Pharmaceutical Sciences, Tohoku University)
Dr. Moriguchi began his dementia research during his study abroad at Northwestern University (USA, 2001-2004). After joining Tohoku University as a faculty member in 2004, he focused on calcium signaling in neurons, engaging in dementia drug discovery research and elucidating the disease mechanisms of cognitive and psychiatric disorders. In 2022, he founded Neusignal Therapeutics, Inc. to accelerate the development of novel dementia therapeutics. He holds a Ph.D. in Pharmaceutical Sciences from the Graduate School of Pharmaceutical Sciences, Kyushu University.

Makiko Uno
Ph.D., MBA
Chief Development Officer

At Daiichi Sankyo Company, Limited, Dr. Uno was initially involved in exploratory research, including target molecule identification, lead compound discovery, and mechanistic analysis. She then transitioned to Global Regulatory Affairs, gaining experience in IND/CTA/CTN and NDA/MAA submissions in Japan, the U.S., and Europe. Later, she served as a Global Project Leader in Clinical Development, and managed and oversaw domestic medical strategy planning and execution in Medical Affairs. She holds a B.A. from University of Tokyo and a Ph.D. in Science from the Graduate School of Science, University of Tokyo.

Makoto Takeuchi
Outside Director

Executive Vice President at First Track Initiative, Inc.

Yuto Torii, DVM, MBA
Outside Director

Principal at Keio Innovation Initiative, Inc.

Hikaru Ihara, M.D., MBA
Outside Director

Senior Associate at Angel Bridge, Inc.

Shoma Tanaka
Outside Director

Director at DCI Partners Co., Ltd.

Hiroko Kimura, Ph.D.
Auditor

Principal at First Track Initiative, Inc.

MEDICAL ADVISOR

Masashi Aoki
Masashi Aoki
MD, Ph.D.
  • Professor at Department of Neurology, Tohoku University Graduate School of Medicine
  • A member of committee for Clinical Practice Guidelines of ALS and hereditary neurological disorders
  • Director at Clinical Research, Innovation and Education Center, Tohoku University Hospital
  • Earned his MD and Ph.D. from Tohoku University

Atsushi Iwata
Atsushi Iwata
MD, Ph.D.
  • Vice President at Tokyo Metropolitan Institute for Geriatrics and Gerontology
  • Director at Metropolitan Geriatric Medical Center Hospital
  • President at the Japan Society for Dementia
  • Councilor at the Japan Society of Neurology
  • Earned his MD and Ph.D. from the University of Tokyo
Michael S Rafii
Michael S Rafii
MD, Ph.D.
  • Professor of Clinical Neurology, Keck School of Medicine of University of Southern California
  • Medical Director, Epstein Family Alzheimer’s Therapeutic Research Institute
  • Associate Director, Alzheimer’s Clinical Trials Consortium
  • Earned his MD and PhD from Brown University

COMPANY

Company name:Neusignal Therapeutics, Inc.
Founded:April 1, 2022
Representative Director:Itaru Arimoto, Ph.D.
Head Office:Nihonbashi Life Science Building 2, 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo
Core business:Research and development of therapeutic drugs for dementia and psychiatric disorders
Target discovery and research and development of therapeutic drugs for other brain diseases
OfficersItaru Arimoto, Ph.D., Representative Director
Makoto Takeuchi, Outside Director
Yuto Torii, DVM, MBA, Outside Director
Hikaru Ihara, M.D., MBA, Outside Director
Shoma Tanaka, Outside Direcotor
Hiroko Kimura, Ph.D., Auditor
Number of Employees:11 (as of November 1, 2025)
Paid-in capital:¥100,000,000
Our Investors:Fast Track Initiative, Inc.
Keio Innovation Initiative, Inc.
Angel Bridge Inc.
DCI Partners Co., Ltd.
Mitsubishi UFJ Capital Co., Ltd.
NISSAY CAPITAL CO.,LTD.
Mizuho Capital Co., Ltd.
FFG Venture Business Partners Co., Ltd.
SMBC Venture Capital Co., Ltd.
Red Capital Co., Ltd.
Nippon Venture Capital Co., Ltd.
THE GOGIN CAPITAL Co.,Ltd.